Chemical & Engineering News

March 7, 2023

Flagship unveils latest brainchild: Ampersand Biomedicines

Recent News

April 20, 2026

Ampersand Biomedicines Presents Preclinical Data on AMP-220, a Gut-Targeted IL-22 AND-Body™ Therapeutic, at AAI 2026

New data demonstrate the IL-22 AND-Body™ therapeutic, AMP-220, selectively targets gut tissue, conferring improved therapeutic efficacy and tolerability in vivo

April 28, 2025

Ampersand Biomedicines Presents Preclinical Data on AMP-410, a Novel Anti-VEGF/4-1BB Bifunctional AND-Body™ Therapeutic, at AACR 2025

Lead development candidate, AMP-410, is activated only by VEGF signals in tumors and binds to the 4-1BB receptor on immune cells to drive immune response and anti-tumor activity